Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does APIXABAN Cause Prostatic specific antigen increased? 63 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 63 reports of Prostatic specific antigen increased have been filed in association with APIXABAN (ELIQUIS). This represents 0.0% of all adverse event reports for APIXABAN.

63
Reports of Prostatic specific antigen increased with APIXABAN
0.0%
of all APIXABAN reports
0
Deaths
24
Hospitalizations

How Dangerous Is Prostatic specific antigen increased From APIXABAN?

Of the 63 reports, 24 (38.1%) required hospitalization, and 2 (3.2%) were considered life-threatening.

Is Prostatic specific antigen increased Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for APIXABAN. However, 63 reports have been filed with the FAERS database.

What Other Side Effects Does APIXABAN Cause?

Death (18,501) Cerebrovascular accident (7,237) Atrial fibrillation (5,690) Off label use (5,590) Thrombosis (5,298) Fall (5,063) Cardiac disorder (4,917) Haemorrhage (4,770) Dyspnoea (4,379) Gastrointestinal haemorrhage (4,030)

What Other Drugs Cause Prostatic specific antigen increased?

ENZALUTAMIDE (3,731) LEUPROLIDE (2,432) ABIRATERONE (1,581) RADIUM RA-223 DICHLORIDE (449) RELUGOLIX (335) BICALUTAMIDE (322) DOCETAXEL (282) APALUTAMIDE (251) DENOSUMAB (220) LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN (212)

Which APIXABAN Alternatives Have Lower Prostatic specific antigen increased Risk?

APIXABAN vs APOMORPHINE APIXABAN vs APRACLONIDINE APIXABAN vs APREMILAST APIXABAN vs APREPITANT APIXABAN vs APROTININ

Related Pages

APIXABAN Full Profile All Prostatic specific antigen increased Reports All Drugs Causing Prostatic specific antigen increased APIXABAN Demographics